TSX runs higher on rate cut expectations
DUBLIN - Investment firm Citadel Group has disclosed a 1.61% stake in Mural Oncology plc, according to a regulatory filing published Tuesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 280,225 shares representing 1.61% of the company as of August 25, 2025. This includes 252,225 owned and controlled shares and 28,000 shares through stock-settled derivatives.
The filing also reveals Citadel maintains short positions equivalent to 1.24% of Mural Oncology’s shares, primarily through stock-settled derivatives including options.
The disclosure details multiple transactions conducted on August 25, with Citadel both buying and selling Mural Oncology shares at prices ranging from $2.05 to $2.08 per share.
Mural Oncology, an Ireland-based biopharmaceutical company, trades on the Irish stock exchange with shares priced in U.S. dollars. The company’s common stock carries the international securities identification number (ISIN) IE000LK2BOB4.
The position disclosure was required under Rule 8.3 of the Irish Takeover Panel Act, which mandates that entities holding interests of 1% or more in a company involved in a potential takeover must disclose their positions.
The filing, submitted as Form 8.3, includes a supplemental disclosure detailing Citadel’s options positions with various strike prices and expiration dates extending through January 2027.
This information is based on a regulatory disclosure statement filed with the Irish Takeover Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.